Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenadoxone SCHEMBL2032631 | 0.99 | OPRM1 (0.62) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Phenadoxone SCHEMBL9858401 | 0.96 | OPRM1 (0.59) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Phenadoxone SCHEMBL11319633 | 0.94 | OPRM1 (0.57) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Dipipanone SCHEMBL25367 | 0.87 | OPRM1 (0.57) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Dipipanone SCHEMBL392119 | 0.86 | OPRM1 (0.56) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Phenadoxone SCHEMBL6912655 | 0.83 | TSHR (0.48) | OPRM1OPRD1SMN1; SMN2ALDH1A1TSHR | |
| Dextromoramide SCHEMBL29395675 | 0.82 | SMN1; SMN2 (0.51) | OPRM1OPRD1KCNA5SMN1; SMN2CYP3A4 | |
| SCHEMBL9917093 | 0.81 | OPRM1 (0.50) | OPRM1OPRD1GRIN2DGRIN1GRIN2A | |
| Dextromoramide SCHEMBL29581857 | 0.78 | SMN1; SMN2 (0.46) | OPRM1OPRD1KCNA5SMN1; SMN2CYP3A4 | |
| SCHEMBL9917096 | 0.74 | SLC6A2 (0.43) | OPRM1OPRD1GRIN2DGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6678 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| EP-0731694-A4 | — | — | 1996-10-02 | — | — | EP | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0415693-A1 | Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence | ARIZONA TECHNOLOGY DEVELOPMENT CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |